IRLAB has Completed a Successful End-of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam
GOTHENBURG, SWEDEN / ACCESSWIRE / February 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 22 February 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ...
Vastra Gotalands Lan Gunnar Olsson Arvid Carlsson Michaelj Fox Foundation Nasdaq Stockholm Nobel Laureate
Source: yahoo.com